Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S065 - Therapeutic and Diagnostic Pearls

Tuesday, March 5; 8:00 AM - 10:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss pragmatic therapeutic and diagnostic points which can be incorporated into practice
  • Describe useful, new or evolving therapeutic interventions for skin disorders

Description

This session will highlight important diagnostic and therapeutic pearls and is directed towards both novice and experienced clinicians. Information discussed will be based on both peer-reviewed literature and the result of personal experience.

Disclosures

  • DeKlotz, Cynthia, MD: Allergan, Inc – I(Grants/Research Funding); Anacor Pharmaceuticals, Inc. – I(Fees); Pfizer Inc. – I(Fees); Pierre Fabre Dermatologie – A(Fees); PIQUR Therapeutics – C(Fees); Sanofi/Regeneron – A(Fees), I(Fees); Scioderm – I(Fees); Stiefel a GSK company – A(H);
  • Eichenfield, Lawrence F., MD: Abbvie – I(Grants/Research Funding); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana BioSciences – Data Safety Monitoring Board(H); Cutanea Life Sciences – C(H); Dermavant Sciences, Inc. – C(H); Dermira – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Forte – A(H); Galderma Laboratories, L.P. – C(H), I(Fees); Glenmark Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Matrisys – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H); Pfizer – I(Grants/Research Funding); Pfizer Inc. – C(H); Sanofi/Regeneron – C(H), I(Fees); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); verrica – A(SO); Verrica – C(H); verrica – I(Grants/Research Funding); Wiley-Blackwell – O(H);
  • Jorizzo, Joseph L., MD: Amgen – A(H); LEO Pharma, US – A(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Marghoob, Ashfaq A., MD: 3Gen, LLC – C(NC), O(EQ), O(NC), SP(H); American Dermoscopy Meeting – F(OB); Canfield Scientific, Inc. – C(NC), O(EQ), O(NC); Heine – C(NC), O(EQ); Informa HealthCare – O(OB); JP Medical Publishers – O(OB); Springer Publishing – O(OB); UpToDate, Inc – O(H);
  • Ortiz, Arisa, MD: Aerolase – A(H), O(EQ); Alastin Skincare, Inc – C(H); Allergan, Inc – A(H), SH(NC), SP(H); BTL Industries – O(EQ); Cutera, Inc. – C(H); Guthy-Renker – SP(S); InMode MD Ltd – A(H), SP(H); Merz Aesthetics – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Rodan and Fields – A(H); Sciton Inc. – A(H), SP(H); Sienna Biopharmaceuticals – I(Grants/Research Funding); Ulthera – Data Safety Monitoring Board(H);
  • Paravar, Taraneh, MD: UpToDate, Inc – O(H);
  • Shapiro, Jerry, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc. – A(H); Applied Biology – C(H); Bayer Consumer Healthcare Pharmaceuticals – C(NC); Bioniz Therapeutics – A(Fees); Cassiopea SpA – A(NC); Incyte Corporation – C(NC); Johnson & Johnson Consumer Products Company – C(H); L'Oréal France – C(H); RegenLab – I(Grants/Research Funding); RepliCel Life Sciences – F(ST); Samumed, LLC – A(H);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Schedule
Tuesday, March 5
8:00 AM
Dr. Eichenfield and Dr. Paravar / Introduction
8:01 AM
Dr. Shapiro / What is new in hair loss disorders
8:15 AM
Dr. Shapiro / Q&A
8:17 AM
Dr. DeKlotz / Practical Pediatric Pearls
8:31 AM
Dr. DeKlotz / Q&A
8:33 AM
Dr. Lebwohl / Psoriasis Pearls
8:47 AM
Dr. Lebwohl / Q&A
8:49 AM
Dr. Tomecki / ID Update: What’s New in Rx
9:03 AM
Dr. Tomecki / Q&A
9:05 AM
Dr. Jorizzo / Topical adjunctive treatment of desquamative gingivitis
9:19 AM
Dr. Jorizzo / Q&A
9:21 AM
Dr. Marghoob / Diagnostic Dermoscopic Pearls
9:35 AM
Dr. Marghoob / Q&A
9:37 AM
Dr. Ortiz / Cosmetic & Laser Pearls to Optimize Your Aesthetic Practice
9:51 AM
Dr. Ortiz / Q&A
Event Details
  • Date
    Tuesday, March 5
  • Time
    8:00 AM - 10:00 AM
  • Location
    Ballroom C
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Lawrence F. Eichenfield, MD, FAAD
  • Taraneh Paravar, MD, FAAD
Speakers
  • Arisa Ortiz, MD, FAAD - Handout
  • Ashfaq A. Marghoob, MD, FAAD - Handout
  • Cynthia DeKlotz, MD, FAAD
  • Jerry Shapiro, MD, FAAD
  • Joseph L. Jorizzo, MD, FAAD - Handout
  • Kenneth J. Tomecki, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout